On Thursday shares of Leju Holdings Limited (NYSE:LEJU) closed at $10.53. Leju Holdings Limited (NYSE: LEJU) announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2014 with the Securities and Exchange Commission on April 21, 2015.
Comstock Resources Inc. (NYSE:CRK) in last trading activity moved up 5.29% to close at $5.37. Company weekly performance is 14.99% while its quarterly performance stands at 42.44%. Comstock Resources Inc. (NYSE:CRK) is -81.40% away from its 52 week high. Analysts at KLR Group reiterated a “buy” rating and set a $7.00 price target on shares of Comstock Resources (NYSE:CRK) in a research note.
On last trading day BlackBerry Ltd (NASDAQ:BBRY) fell -2.03% to close at $10.16. Its volatility for the week is 2.25% while volatility for the month is 2.77%. BBRY’s sales growth for past 5 years was -25.90% and its EPS growth for past 5 years was -16.40%. BlackBerry Ltd (NASDAQ:BBRY) monthly performance is 13.77%. BlackBerry Ltd and NantHealth, a healthcare-focused data provider, launched a secure cancer genome browser on Sunday, giving doctors the ability to access patients’ genetic data on the BlackBerry Passport smartphone.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has 0.80% insider ownership while its institutional ownership stands at 98.00%. In last trading activity company’s stock closed at $12.67. Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the following three upcoming conferences: Deutsche Bank Securities 40th Annual Health Care Conference, Boston, May 7th, at 1:30 p.m. ET and Bank of America Merrill Lynch 2015 Health Care Conference, Las Vegas, May 12th, at 5:00 p.m. PT (8:00 p.m. ET).
On last trading day Bio-Rad Laboratories, Inc. (NYSE:BIO) fell -0.88% to close at $134.45. Its volatility for the week is 1.67% while volatility for the month is 1.29%. BIO’s sales growth for past 5 years was 4.00% and its EPS growth for past 5 years was -10.10%. Bio-Rad Laboratories, Inc. (NYSE:BIO) monthly performance is -0.54%. On 28 April, Bio-Rad Laboratories, Inc. (NYSE:BIO) have announced the launch of two PrimePCR™ Assay Kits for Droplet Digital PCR (ddPCR™) (ddPCR™). This release expands Bio-Rad’s offering of predesigned, fully wet-lab validated assays with kits for SMN1 and SMN2 copy number determination. These targets are commonly studied genes associated with Spinal Muscular Atrophy (SMA).